Home Ingredients Lactobacillus gasseri BNR17

Lactobacillus gasseri BNR17

Lactobacillus gasseri
Evidence Level
Limited
4 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

Lactobacillus gasseri BNR17 is a live probiotic strain isolated from the breast milk of a Korean mother and deposited as KCTC 10902BP. It was developed by Bioneer Corporation of Korea and is now held by its probiotics company AceBiome, which sells it in Korea under the BNRThin name; in the US it appears in single-strain capsules and in blends under license. In a 12-week trial in 90 adults with a higher BMI, 10 billion CFU a day lowered visceral fat area more than placebo, while an earlier 12-week trial found no difference in body weight, its stated main outcome. A larger registered trial with visceral fat as its main outcome finished in 2021 and has no published results. Two small Korean bowel symptom trials found lower abdominal pain or loose-stool ratings than placebo on some of many measures, and one never reported its registered main outcome.

Studied Dose 10 billion CFU a day in capsules for 4 to 12 weeks in most trials. One body fat trial also tested 1 billion CFU a day, and a 4-week bowel symptom trial also tested 200 million and 2 billion CFU a day. A US single-strain label read lists 10 billion CFU per capsule, once daily.
Active Compound Live cells of the single strain Lactobacillus gasseri BNR17, isolated from human breast milk and deposited at the Korean Collection for Type Cultures as KCTC 10902BP under a Bioneer Corporation patent. BNR17 is a trademark of AceBiome, Bioneer's probiotics company; US labels state the strain is made by Chr. Hansen under license. Trials used capsules of freeze-dried cells compared with filler-only capsules.

Benefits

Visceral fat area in adults with a higher BMI

In 90 adults with a BMI of 25 to 35, 10 billion CFU a day for 12 weeks lowered CT visceral fat area more than placebo, a 21.6 cm2 difference (P = .012); the 1 billion CFU dose was not reported to differ. Waist size fell from baseline on both doses but not on placebo, and blood markers did not differ. The abstract names no main outcome; the registry entry, filed after enrollment began, lists three CT fat areas.

Supported by Trial 1, Trial 4

Body weight and waist size over 12 weeks

In 57 adults with a BMI of 23 or more and fasting glucose of at least 100 mg/dL, 10 billion CFU a day for 12 weeks did not change body weight compared with placebo, the stated main outcome. Weight fell about 1.1 kg and waist about 2 cm within the strain group only, and CT visceral fat, body fat percentage and blood lipids did not differ between groups.

Supported by Trial 2, Trial 1

Loose stools and abdominal pain ratings over 8 weeks

In 51 of 60 adults with diarrhea-predominant IBS analyzed after 8 weeks, 10 billion CFU a day improved diarrhea ratings in 67% versus 26% on placebo and lowered several quality-of-life scores such as abdominal pain and bloating. The stated main outcome was broad bowel function across many questionnaires, overall self-rated relief did not differ, and no correction was made for multiple tests.

Supported by Trial 3

Abdominal pain ratings at four daily doses

In a 4-week dose-finding trial in adults with a BMI over 23 and self-reported bowel symptoms, only the 10 billion CFU a day dose lowered abdominal pain scores more than placebo (P = 0.020, n = 10 versus 12); bloating and emptying scores improved in every group, placebo included. The registered main outcome was glucose tolerance, which was not reported, and 13 of 55 were not analyzed.

Supported by Trial 4, Trial 3

Strain recovery in stool after daily intake

In the 4-week dose-finding trial, a strain-specific test found BNR17 in stool from 7 of 9, 10 of 11 and 9 of 10 people on 200 million, 2 billion and 10 billion CFU a day, and in none of 12 on placebo. Total fecal lactobacilli rose most on the highest dose. This shows the strain passed through the gut alive.

Supported by Trial 4, Trial 1

Fasting blood sugar over 8 to 12 weeks

In the 8-week bowel trial, median fasting glucose fell from 101.5 to 97.5 mg/dL within the strain group, but the change did not differ from placebo (P = 0.307); HbA1c and insulin did not change. In the 12-week weight trial in adults with fasting glucose of at least 100 mg/dL, glucose and insulin did not differ between groups, and a 4-week trial registered with glucose tolerance as its main outcome never reported it.

Supported by Trial 2, Trial 1

Mechanism of action

1

Less weight and fat gain on sugar-rich diets in rodents (animal work)

In rats on a high-carbohydrate diet for 12 weeks and mice on a high-sucrose diet for 10 weeks, BNR17 limited weight and white fat gain, raised fat-burning gene activity and lowered leptin and insulin in mice. Bioneer scientists ran these studies, and the human weight trials found smaller or no changes.

2

Blood glucose in diabetic mice (animal work)

In db/db mice given BNR17 twice a day for 12 weeks, the highest dose lowered fasting and 2-hour blood glucose compared with untreated mice and improved glucose tolerance in a dose-dependent way, while body weight did not fall. Human trials have not shown a between-group effect on blood sugar.

3

Fecal exopolysaccharides and sugar transport genes in mice (animal work)

In mice on a high-sucrose diet, BNR17 raised fecal exopolysaccharides and tended to lower gut sugar transporter gene activity, which the authors read as reduced sugar absorption. All authors work for AceBiome, and this has not been measured in people.

Clinical trials

1
BNR17 at Two Doses for 12 Weeks: Visceral Fat in 90 Adults With a Higher BMI
PubMed

Randomized, double-blind, placebo-controlled trial; placebo, 1 billion (10^9) or 10 billion (10^10) CFU of BNR17 a day for 12 weeks, with CT abdominal fat areas, body composition and blood markers measured at the start and end; the abstract names no primary outcome, while the Korean registry entry KCT0000756 (registered about three weeks after enrollment began, sponsored and funded by Bioneer and the Ministry of Agriculture, Food and Rural Affairs) lists CT total, visceral and subcutaneous fat areas as primary; authors are at a contract research organization, Seoul National University Hospital and Ewha Womans University, none listed at Bioneer; full text not read (Kim et al. 2018, J Med Food)

90 Korean adults aged 20 to 75 with a BMI of 25 to 35, randomized to three groups.

Visceral fat area fell more on 10 billion CFU a day than on placebo (P = .038), and the 12-week difference versus placebo was -21.6 cm2 (P = .012); with two dose arms, only the P = .012 result clears a Bonferroni threshold of .025, and results for total and subcutaneous fat areas are not given in the abstract. Waist size fell from baseline on both doses (P = .045 and .012) but not on placebo. Blood markers did not differ among groups.

2
BNR17 for 12 Weeks: Body Weight in 62 Adults With Overweight and Higher Fasting Glucose
PubMed

Single-center, randomized, double-blind, placebo-controlled trial; 10 billion (10^10) CFU of BNR17 a day as six capsules (two before each meal) with trehalose, skim milk and fructooligosaccharide filler, or filler-only capsules, for 12 weeks with no diet or exercise changes; the stated primary end point was the rate of weight reduction, and the trial was powered to detect a 2.5 kg difference; no registry number is reported; funded by Bioneer through a contract research organization, and three of seven authors work at Bioneer's R&D center (Jung et al. 2013, Korean J Fam Med)

62 Korean adults aged 19 to 60 with a BMI of 23 or more and fasting blood glucose of at least 100 mg/dL (31 per group); the paper reports 8 withdrawals (6 strain, 2 placebo) yet analyzes 57.

Body weight, the primary outcome, did not differ between groups at 12 weeks. Within the strain group, weight fell 1.1 kg, BMI 0.5 kg/m2 and waist 2 cm, but none of these differed from placebo, and CT visceral fat, body fat percentage, fasting glucose, insulin and blood lipids did not change between groups. No adverse reactions were judged related to the capsules; hematocrit changed in the strain group.

3
BNR17 for 8 Weeks: Bowel Symptoms in 60 Adults With Frequent Loose Stools
PubMed

Single-center, randomized, double-blind, placebo-controlled trial (KCT0000969); four capsules a day providing 10 billion (10^10) CFU of BNR17 from Bioneer, or maltodextrin capsules, for 8 weeks; the stated primary end point was improvement of bowel function, measured with several questionnaires, a stool chart and colon transit time, analyzed per protocol without correction for multiple tests; the paper credits Korean government ministries and declares no conflicts, while the registry entry (filed December 31, 2013, after enrollment began December 6) also lists Bioneer Corporation as a funder and names a bowel function questionnaire as the primary outcome; no Bioneer authors are listed (Shin et al. 2018, J Clin Biochem Nutr)

60 Korean adults aged 20 to 55 with diarrhea-predominant IBS by Rome III criteria (30 per group); 51 analyzed (24 strain, 27 placebo).

Diarrhea ratings improved in 16 of 24 on the strain versus 7 of 27 on placebo (p < 0.01), and scores for abdominal pain, bloating, satisfaction with bowel movements and disruption of daily life fell more than on placebo (p < 0.05). Overall self-rated symptom improvement did not differ. Colon transit time lengthened within the strain group only; the authors state the between-group difference was not significant. Safety blood tests did not change.

4
BNR17 at Three Doses for 4 Weeks: Bowel Symptom Scores in 55 Adults
PubMed

Randomized, double-blind, placebo-controlled, dose-finding trial (KCT0000368) with a 7-day run-in; placebo (dextrin), 200 million, 2 billion or 10 billion CFU of BNR17 a day supplied by Bioneer for 4 weeks; symptom scores on a five-point scale and fecal strain detection were assessed, the paper states no primary outcome, but the registry entry (filed February 24, 2012, after enrollment began February 6, and titled as a glucose tolerance pilot study) lists the oral glucose tolerance test as primary and the bowel questionnaire as secondary, and no glucose tolerance results are reported; Dunnett's test was used for comparisons with placebo; the paper credits the National Research Foundation of Korea, while the registry also lists Bioneer as a funder; no Bioneer authors are listed (Kim et al. 2018, Food Sci Biotechnol)

55 Korean adults over 20 with a BMI over 23 and self-reported bowel symptoms (the registry also lists a 30-minute post-glucose-load blood glucose threshold of 140 mg/dL as an entry criterion); 42 analyzed (12 placebo, 9, 11 and 10 on the three doses).

Abdominal pain scores fell more than placebo on 10 billion CFU a day only (P = 0.020). Bloating and incomplete emptying improved from baseline in every group, placebo included, with no between-group difference reported. BNR17 was found in stool in 7 of 9, 10 of 11 and 9 of 10 on the three doses and in none on placebo. Adverse events were not reported.

Side effects and drug interactions

Common Potential side effects

In the 12-week weight trial, no adverse reactions were judged related to the capsules; one person on the strain reported diarrhea and one on placebo reported nausea. A small hematocrit change was seen in the strain group, and the 8-week bowel trial also noted a slight hematocrit decrease without other changes.
In the 8-week bowel trial, vital signs, blood counts, liver and kidney tests and urinalysis did not change in either group. Trials lasted up to 12 weeks.
One trial product used skim milk in its capsule filler, so people with a milk allergy should check the label. People who are severely immunocompromised or critically ill should ask a doctor before taking live probiotics.

Important Drug interactions

No drug interaction studies of BNR17 were found; the points below are general precautions for live probiotics.
Antibiotics can kill live probiotic bacteria; ask a pharmacist how to space a probiotic around antibiotic doses.
Immunosuppressive drugs or chemotherapy: ask a doctor before using any live probiotic.

Explore Other Ingredients

Metabolic Health
Berberine
Berberine is a yellow alkaloid found in plants such as barberry, goldenseal and Chinese go…
GlucoVantage® (Dihydroberberine)
GlucoVantage® is NNB Nutrition's branded dihydroberberine (DHB), a reduced form of berberi…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a sugar-like compound that the body makes from glucose and that takes part in…

Frequently asked questions about Lactobacillus gasseri BNR17

Is BNR17 the same as other Lactobacillus gasseri strains such as SBT2055?

No. BNR17 is a separate strain isolated from breast milk in Korea and held by AceBiome, while SBT2055 is a Japanese strain owned by Megmilk Snow Brand. With probiotics, results belong to the strain tested, so check that a label names BNR17.

What did the body fat trials of BNR17 find?

In 90 adults with a higher BMI, 10 billion CFU a day for 12 weeks lowered visceral fat area by about 22 cm2 more than placebo, while a lower dose was not reported to differ. An earlier 12-week trial found no difference in body weight, its main outcome, and a larger registered trial finished in 2021 without published results.

How much BNR17 was used in studies?

Most trials used 10 billion CFU a day in capsules for 4 to 12 weeks. Lower doses of 200 million to 2 billion CFU were tested in two trials and showed fewer or no differences from placebo. A US single-strain label read lists 10 billion CFU in one daily capsule.

Is BNR17 safe?

In trials of up to 12 weeks, no adverse reactions were judged related to BNR17, and safety blood tests were stable apart from a small hematocrit change. People who are severely immunocompromised or critically ill should ask a doctor before taking live probiotics.

What is Lactobacillus gasseri BNR17?

Lactobacillus gasseri BNR17 is a live probiotic strain isolated from the breast milk of a Korean mother and deposited as KCTC 10902BP. It was developed by Bioneer Corporation of Korea and is now held by its probiotics company AceBiome, which sells it in Korea under the BNRThin name; in the US it appears in single-strai…

What is Lactobacillus gasseri BNR17 used for?

NutraSmarts does not list Lactobacillus gasseri BNR17 under a health category. What the research covers: In 90 adults with a BMI of 25 to 35, 10 billion CFU a day for 12 weeks lowered CT visceral fat area more than placebo, a 21.6 cm2 difference (P = .012); the 1 billion CFU dose was not reported to differ.

Does Lactobacillus gasseri BNR17 interact with any medications?

Possible interactions include: No drug interaction studies of BNR17 were found; the points below are general precautions for live probiotics. Antibiotics can kill live probiotic bacteria; ask a pharmacist how to space a probiotic around antibiotic doses. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Lactobacillus gasseri BNR17?

NutraSmarts rates the evidence for Lactobacillus gasseri BNR17 as Limited (2 out of 5). It is backed by 4 study summaries and 16 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(16 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Med Food. 2018;21(5):454-461. doi: 10.1089/jmf.2017.3937.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 90 adults aged 20 to 75 with a BMI of 25 to 35: placebo, 10^9 or 10^10 CFU of BNR17 a day for 12 weeks. Visceral fat area fell more on the high dose than on placebo (P = .038), with a 12-week difference of -21.6 cm2 (P = .012); waist circumference fell from baseline on both doses (P = .045 and .012) but not on placebo; blood markers did not differ. The abstract states no primary outcome. Authors are at Biofood CRO, Seoul National University Hospital and Ewha Womans University. Abstract read; full text is paywalled and was not read.
  2. Jung SP, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, Kim JY. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med. 2013;34(2):80-9. doi: 10.4082/kjfm.2013.34.2.80.PubMedUsed to support: Single-center randomized double-blind placebo-controlled trial (full text read) in 62 Korean adults aged 19 to 60 with a BMI of 23 or more and fasting glucose of at least 100 mg/dL: 10^10 CFU of BNR17 a day as six capsules, or filler capsules, for 12 weeks. The stated primary end point, weight reduction, did not differ between groups; within the strain group weight fell 1.1 kg and waist 2 cm, without between-group differences, and CT visceral fat, glucose, insulin and lipids did not differ. No related adverse reactions. Funded by Bioneer via Solomon Contract Research Organization; three of seven authors are at Bioneer's R&D center; no registry number reported.
  3. Shin SP, Choi YM, Kim WH, Hong SP, Park JM, Kim J, Kwon O, Lee EH, Hahm KB. A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome. J Clin Biochem Nutr. 2018;62(2):179-186. doi: 10.3164/jcbn.17-73.PubMedUsed to support: Single-center randomized double-blind placebo-controlled trial (KCT0000969; full text read) in 60 adults aged 20 to 55 with diarrhea-predominant IBS: 10^10 CFU of BNR17 a day (Bioneer capsules) or maltodextrin for 8 weeks; 51 analyzed per protocol. Diarrhea ratings improved in 16 of 24 versus 7 of 27 (p < 0.01) and several quality-of-life scores, including abdominal pain and bloating, fell more than placebo (p < 0.05, uncorrected); overall self-rated improvement did not differ. Fasting glucose fell from 101.5 to 97.5 mg/dL within the strain group only. Safety tests unchanged. Funded by Korean government ministries per the paper, with no conflicts declared; the registry entry, filed after enrollment began, also lists Bioneer Corporation as a funder and a bowel function questionnaire as the primary outcome. Between-group change in fasting glucose: P = 0.307.
  4. Kim JY, Park YJ, Lee HJ, Park MY, Kwon O. Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial. Food Sci Biotechnol. 2018;27(3):853-857. doi: 10.1007/s10068-017-0296-7.PubMedUsed to support: Randomized double-blind placebo-controlled dose-finding trial (KCT0000368; full text read on PMC) in 55 adults over 20 with a BMI over 23 and self-reported bowel symptoms: placebo, 2 x 10^8, 2 x 10^9 or 10^10 CFU of BNR17 a day for 4 weeks; 42 analyzed. Abdominal pain scores fell more than placebo on the highest dose only (P = 0.020); bloating and incomplete emptying improved in all groups including placebo. BNR17 was detected in stool in 7 of 9, 10 of 11 and 9 of 10 on the three doses and 0 of 12 on placebo. Strain supplied by Bioneer; funded by the National Research Foundation of Korea per the paper, with no conflicts declared; the registry entry (KCT0000368), filed after enrollment began, lists Bioneer as a funder and the oral glucose tolerance test as the primary outcome, which the paper does not report.
  5. Kang JH, Yun SI, Park HO. Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol. 2010;48(5):712-4. doi: 10.1007/s12275-010-0363-8.PubMedUsed to support: Animal study by Bioneer R&D researchers: rats fed a high-carbohydrate diet and given BNR17 twice daily for 12 weeks had a smaller percent increase in body weight (P = 0.0331) and fat pad mass (P < 0.01) than untreated rats.
  6. Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One. 2013;8(1):e54617. doi: 10.1371/journal.pone.0054617.PubMedUsed to support: Animal study: in C57BL/6J mice on a high-sucrose diet for 10 weeks, BNR17 at 10^9 or 10^10 CFU reduced body weight and white fat weight, raised fatty acid oxidation gene expression and GLUT4, lowered fatty acid synthesis genes and lowered serum leptin and insulin. All authors are employed by Bioneer, which holds patents on the strain.
  7. Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol. 2009;107(5):1681-6. doi: 10.1111/j.1365-2672.2009.04350.x.PubMedUsed to support: Animal study by Bioneer R&D researchers: in db/db mice given BNR17 (10^7 to 10^10 CFU) twice daily for 12 weeks, fasting and 2-hour blood glucose were lower than in controls on the 10^10 CFU dose, glucose tolerance improved with dose, HbA1c fell without significance and body weight did not fall.
  8. Jo YM, Son YJ, Kim SA, Lee GM, Ahn CW, Park HO, Yun JH. Lactobacillus gasseri BNR17 and Limosilactobacillus fermentum ABF21069 Ameliorate High Sucrose-Induced Obesity and Fatty Liver via Exopolysaccharide Production and β-oxidation. J Microbiol. 2024;62(10):907-918. doi: 10.1007/s12275-024-00173-6.PubMedUsed to support: Animal study in C57BL/6 mice on a high-sucrose diet: BNR17, another strain and their combination were tested; the probiotic groups, particularly BNR17, raised fecal exopolysaccharides and tended to lower intestinal sugar transport gene expression, and the combination reduced body weight, fat and liver fat. All authors are employed by AceBiome.
  9. Shehata HR, Ragupathy S, Allen S, Leyer G, Newmaster SG. Real-Time PCR Assays for the Specific Identification of Probiotic Strains Lactobacillus gasseri BNR17 and Lactobacillus reuteri LRC (NCIMB 30242). Probiotics Antimicrob Proteins. 2021;13(3):837-846. doi: 10.1007/s12602-020-09695-y.PubMedUsed to support: Lab method study by University of Guelph and UAS Laboratories authors: a validated probe-based real-time PCR assay identifies BNR17 at the strain level with 100% true positive and 0% false positive rates, allowing products to be checked for the named strain.
  10. UAS Labs LLC. Effect of a Probiotic, Lactobacillus Gasseri BNR17, on Body Composition and Weight Management in Overweight Adults (NCT04260997) ClinicalTrials.gov. 2026;Registry record NCT04260997, first posted February 7, 2020, last updated September 29, 2021; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (registry record). Randomized, quadruple-blind, placebo-controlled trial sponsored by UAS Labs at a site in Cork, Ireland: one BNR17 or placebo capsule a day for 12 weeks in overweight adults, 125 enrolled. Registered primary outcome: change in DXA visceral fat at 12 weeks; secondary outcomes include fat mass, weight, waist, glucose, HbA1c and insulin. Completed September 2021; no results are posted and no matching publication was found in PubMed or Europe PMC.
  11. Korea Disease Control and Prevention Agency, Clinical Research Information Service. Effect of Lactobacillus gasseri BNR17 consumption on body fat reduction in obese adults (KCT0000756) Clinical Research Information Service (CRIS), via WHO ICTRP. 2026;Registry record KCT0000756, registered May 29, 2013; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (registry record read via WHO ICTRP). Primary sponsor Bioneer; funding Bioneer and the Ministry of Agriculture, Food and Rural Affairs; first enrollment May 8, 2013, registered May 29, 2013 (not prospective); target 90 adults with a BMI of 25 to 35 at Seoul National University Hospital; 10^9 or 10^10 CFU a day for 12 weeks. Primary outcome: CT abdominal fat area (total, visceral and subcutaneous). Status completed; no results posted. This is the registration of the 90-person trial published in 2018.
  12. Bioneer Corporation; Kang JH, You BI, Yun SI, Park HO. Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation (US 8,309,076 B2) Google Patents. 2012;US patent 8,309,076 B2, granted November 13, 2012; priority August 4, 2006; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (patent record). Assignee Bioneer Corp. Describes Lactobacillus gasseri BNR17 isolated from the breast milk of a Korean woman within two weeks of giving birth and deposited at the Korean Collection for Type Cultures as KCTC 10902BP on January 23, 2006; lists reissues RE46912 and RE48652.
  13. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label Database: labels listing Lactobacillus gasseri BNR17 (Dr. Mercola Biothin Probiotic 10 Billion CFU; Renew Life Probiotics Healthy Weight Support 20 Billion CFU) NIH Dietary Supplement Label Database. 2026;DSLD label IDs 327105 and 306947; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (US label database). One label lists 10 billion CFU of Lactobacillus gasseri BNR17 in one capsule a day and states that BNR17 is a trademark of AceBiome/Bioneer, made by Chr. Hansen and used under license. Another lists BNR17 in a 10-strain blend with green coffee bean extract, with no amount for the strain, and calls AceBiome a probiotics company of Bioneer.
  14. van Hal J. AceBiome CEO unpacks science behind South Korea's first probiotic for body fat reduction Nutrition Insight. 2025;Published August 6, 2025; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (trade press interview). AceBiome sells the strain in Korea as BNRThin capsules, sticks and protein products at 10 billion CFU a day; the company states BNR17 was the first probiotic approved by the Korean Ministry of Food and Drug Safety for body fat reduction (a company statement not checked against the ministry's records). AceBiome describes a partnership, begun with UAS Labs in 2018 and continued through Chr. Hansen and Novonesis, that gives it access to fermentation and freeze-drying capabilities.
  15. Korea Disease Control and Prevention Agency, Clinical Research Information Service. Effect of Lactobacillus gasseri BNR17 on bowel function in Irritable Bowel Syndrome with diarrhea (KCT0000969) Clinical Research Information Service (CRIS), via WHO ICTRP. 2026;Registry record KCT0000969, registered December 31, 2013; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (registry record read via WHO ICTRP). Primary sponsor Ewha Womans University; funding from the Ministry of Science, ICT and Future Planning, the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries, and Bioneer Corporation; first enrollment December 6, 2013, registered December 31, 2013 (not prospective); target 60 adults aged 20 to 55 with diarrhea-predominant IBS; BNR17 or placebo for 8 weeks. Primary outcome: questionnaire for bowel function; secondary: colonic transit time and blood glucose markers. This is the registration of the 8-week trial published in 2018.
  16. Korea Disease Control and Prevention Agency, Clinical Research Information Service. Effect of Lactobacillus gasseri BNR17 on glucose tolerance (Pilot study) (KCT0000368) Clinical Research Information Service (CRIS), via WHO ICTRP. 2026;Registry record KCT0000368, registered February 24, 2012; accessed November 12, 2026..SourceUsed to support: Not PubMed-indexed (registry record read via WHO ICTRP). Primary sponsor Ewha Womans University; funding from Bioneer, the Ministry of Science, ICT and Future Planning, and the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries; first enrollment February 6, 2012, registered February 24, 2012 (not prospective); target 52 adults over 20 with a BMI of at least 23, a 30-minute post-load glucose threshold of 140 mg/dL and self-reported bowel symptoms; low, medium or high dose or placebo for 4 weeks. Primary outcome: oral glucose tolerance test; secondary: fecal BNR17, fecal interleukin-10, and a bowel habit and satiety questionnaire. This is the registration of the 4-week dose-finding trial published in 2018, which does not report glucose tolerance.